12/03/2002
FOR IMMEDIATE RELEASE: U.S. Microbics Inc
U.S. Microbics Field Trial Achieves 34% Increase in Sugar Cane Production Proprietary Growing Program Could Increase Worldwide Sugar Cane Production
CARLSBAD, CA, Dec. 3 -/E-Wire/-- U.S. Microbics Inc. (OTCBB:BUGS) announced today that Natura Agricultura, the Mexico operating subsidiary of Bio-Con Microbes Inc., which specializes in agricultural products and services, has completed a rigorous 18-month field trial of the BioSystem Microbic Treatment.
Achieving better than expected growth results, the field trial showed a combined 34% increase in sugar cane yield and sugar cane content without the use of commercial fertilizer products.
The BioSystem Microbic Treatment consists of U.S. Microbics' proprietary blend of natural microbes, developed and tested over 30 years by the late George M. Robinson, his daughter Mery C. Robinson, and Rene Palomares, the president of Natura Agricultura of Culiacan, Mexico.
Palomares commented, "It is gratifying to see these definitive results tracking so well against our prior sugar cane trials. These results have demonstrated the possible increases in worldwide sugar cane production that can be expected using our BioSystem growing program. We anticipate significant sales to sugar cane producers worldwide resulting from definitive trials such as this."
"Results such as these speak for themselves and further validate and quantify the effectiveness and profit potential of microbic treatments within agricultural industries. Not only is agricultural production enhanced with no fertilizer requirements, the process also uses less water so runoff is lessened. Sugar is a multi-billion dollar industry worldwide, and these results present the opportunity for U.S. Microbics to carve a piece of the pie," added Robert C. Brehm, chief executive officer of U.S. Microbics.
Field Trial General Information
The sugar cane plant provided a total of 8 hectares (20 acres) which was divided into two treated areas and two control areas. Each area comprised 2 hectares (5 acres). The trial started at transplanting and continued through harvest, a period of 18 months. Measurements of the sugar cane growth were taken three times during the growing cycle. Sugar Cane height, diameter, and root volume were all measured.
Control Areas
Control received a normal amount of fertilizer including but not limited to: Phosphoric Acid, Potassium Chloride; and Sulfuric Acid.
BioSystem Treated Areas
The BioSystem treated areas received no fertilizer and a proprietary blend of natural microbes.
Results of the Field Trials
Sugar Cane Bore damage averaged 18% in the treated areas and 22% in the control areas. This was a significant reduction of 22% in Cane Bore damage.
The BioSystem applied areas yielded an average of 24.6 Metric Tons per Hectare more than the control areas. This was a yield increase of 14.6%.
More importantly, the BioSystem applied areas yielded 15 more Kilograms of Sugar per Metric Ton of Sugar Cane. This was an increase of 17.65% in sugar content in the cane. Higher sugar content is much more cost effective for the refinery as it saves significantly in harvest, hauling, and milling cost.
Combining the increase in cane yield with the increase in cane sugar content, net sugar production per hectare was 19,437 Kilograms for the treated areas versus 14,417 Kilograms for the control areas. This is an increase of 34.8% in net sugar produced.
About U.S. Microbics Inc.
For further information about U.S. Microbics, contact Justin Keener of USM Capital Group at 760/918-1860, ext. 128 or investor@bugsatwork.com; or learn about the company by visiting its Web site at www.bugsatwork.com. To join the company's mailing list, send your name and email address or fax number to investor@bugsatwork.com.
The information contained in this press release included forward-looking statements usually contains the words "estimate," "anticipate," "believe," "expect," or similar expressions that involve risks and uncertainties. These risks and uncertainties include the company's status as a startup company with uncertain profitability, need for significant capital, uncertainty concerning market acceptance of its products, competition, limited service and manufacturing facilities, dependence on technological developments and protection of its intellectual property. The company's actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences are discussed more fully in the "Risk Factors," "Management Discussion and Analysis or Plan of Operation" and other sections of the company's Form 10-KSB and other publicly available information regarding the company on file with the Securities and Exchange Commission. The company will provide you with copies of this information upon request. This press release does not constitute an offer to buy or sell securities
SOURCE:
U.S. Microbics Inc
12/03/2002
CONTACT:
U.S. Microbics Inc.,
USM Capital Group,
Justin Keener, 760/918-1860, ext. 128,
investor@bugsatwork.com,
WEB SITE:
http://www.bugsatwork.com
http://investor@bugsatwork.com